Financials
Financial year 2025
E-pharma from Antwerpen, company number BE0821059072, closed financial year 2025 with a result of € 108,372 after tax. For that financial year E-pharma recorded a gross margin of € 842,368 and equity of € 497,097. Compared with financial year 2024, the result moved from € -133,408 to € 108,372. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.
€ 497,097
▲ 28% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 108,372
▲ still € 133,408 loss in 2024
Profit after tax over the fiscal year.
€ 101,316
▼ 82% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 472,097.
People and assets in 2025
8.8
▲ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 661,617
▲ € 509,471 vs 2024
€ 75,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 2.2 million
▲ 157% vs 2024
€ 77,779 is repaid this year. At this pace the long-term loan is gone in ≈ 28 years.
€ 36,846
▼ 39% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 136,598
▲ 118% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 119,824 | € 66,013 | € 116,608 | € 842,368 | ▲ € 725,759 |
| Profit after taxes | € 52,625 | € -2,350 | € -133,408 | € 108,372 | ▲ € 241,780 |
| Equity | € 1,062,483 | € 1,060,133 | € 388,725 | € 497,097 | ▲ 28% |
| Total debts | € 2,032,082 | € 2,015,637 | € 2,588,902 | € 2,622,628 | ▲ 1% |
| Cash | € 2,625 | - | € 550,349 | € 101,316 | ▼ 82% |
| Land & buildings | € 435,601 | € 417,451 | € 399,300 | € 381,150 | ▼ 5% |
| Retained profit | € 1,037,483 | € 1,035,133 | € 363,725 | € 472,097 | ▲ 30% |
| Dividend | € 0 | € 0 | € 538,000 | € 0 | ▼ 100% |
| Bank debt | € 1,294,120 | € 1,187,774 | € 838,480 | € 2,151,595 | ▲ 157% |
| Balance sheet total | € 3,094,565 | € 3,075,770 | € 2,977,626 | € 3,119,725 | ▲ 5% |
| Employees (FTE) | - | - | 8.3 | 8.8 | ▲ 0.5 |
Key figures of E-pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to E-pharma?
What happened at E-pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 108,372. Source: NBB ↗
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
From € 52,625 profit in 2022 to € 108,372 profit in 2025.
Paid € 17,542 in corporate taxes since 2022.
Best year ever: 2025, with € 108,372 profit.
On average € 95,700 of value added per employee in 2025.
A new publication or filing at E-pharma? We notify you, reason included.
Follow E-pharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of AMBIXX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
E-pharmaBehind E-pharma is Ambixx BV. The shares are held by AMBIXX (100%). It owns 100% of Apotheek Zwaantje, 100% of Apotheek De Voogt and 100% of Apotheek Cauwenbergh itself.
Directors
According to the 2025 annual accounts
Shareholders
100%
Participations
Establishments
Establishment units
Physical locations of this company
Heidestraat 217
2660 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0821.059.072
- VAT number
- BE 0821.059.072
- Registered office
- Heidestraat 217, 2660 Antwerpen
- Names & denominations
- E-pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 December 2009
- Peppol
- Active · Active since 21 Mar 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van holdings
Holdings
Overige dienstverlenende activiteiten op het gebied van informatie
Overige dienstverlenende activiteiten op het gebied van informatie, n.e. g.